• The global liver disease diagnostics market size was valued at USD 12.98 billion in 2024. The market is projected to grow from USD 13.95 billion in 2025 to USD 21.46 billion by 2032, exhibiting a CAGR of 7.6% during the forecast period.
Email: help@intelmarketresearch.com +91 9169164321
• The global liver disease diagnostics market is witnessing steady growth, driven by the increasing incidence of conditions such as fatty liver disease, hepatitis, and liver cancer. Rising health awareness and the need for early detection are pushing demand for advanced diagnostic tools. Non-invasive techniques, including elastography and MRI, are becoming more common due to their accuracy and patient comfort. Additionally, blood-based biomarker tests are gaining popularity for their ability to detect liver damage at earlier stages. While North America dominates the market due to its well-established healthcare infrastructure, Asia-Pacific is emerging as a fast-growing region owing to a rising patient base and expanding access to diagnostic services. Although high costs and limited availability in lower-income regions pose challenges, ongoing advancements in diagnostic technologies and growing investment in liver health are expected to support future market expansion.
Email:
•Blood Tests
•Biopsy
•Molecular Diagnostics
•Others
• Hepatitis Diagnosis
• Liver Cancer Detection
• Cirrhosis Assessment
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Others
Email: help@intelmarketresearch.com
•Abbott Laboratories (U.S.)
•Roche Diagnostics (Switzerland)
•Thermo Fisher Scientific (U.S.)
•Siemens Healthineers (Germany)
•Becton Dickinson (U.S.)
•Fujifilm Holdings (Japan)
•GE Healthcare (U.S.)
•Canon Medical Systems (Japan)
Email: help@intelmarketresearch.com +91 9169164321
